BIEL (BIEL) Stock Price & Analysis
BIEL (BIEL) rose 16.67% to USD 0 as of September 8, 2026 at 15:26 UTC, according to Nexqual real-time market data.
BIEL last closed at USD 0; the session ranged USD 0–0 on volume of 3,245,380 shares. Market capitalization is —, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, September 8, 2026 at 15:26 UTC.
Key Statistics (as of September 8, 2026 at 15:26 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 16.67% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 3,245,380 shares |
| Market Cap | — |
| Exchange | PNK |
Technical Analysis (BIEL)
Nexqual's technical model rates BIEL "BUY" based on 4 bullish and 1 bearish signals across 126 daily candles, as of September 8, 2026 at 15:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 60.88 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Financial Health Score (BIEL)
Nexqual rates BIEL's overall financial health "Weak" across five dimensions, as of September 8, 2026 at 15:26 UTC.
| Growth | Critical — Revenue -65% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $925 cash vs $13M debt |
| Cash Flow | Weak — FCF negative: -$554K, burning cash |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LLBO | Lifeline BioTechnologies, Inc. | USD 0 | ▲ 60% |
| HTDS | HARD TO TREAT DISEASES INC | USD 0 | ▲ 0% |
| ASFX | AMERICAN SCIENTIFIC RESOURCES I | USD 0 | ▲ 0% |
| HBRM | Herborium Group, Inc. | USD 0 | ▲ 0% |
| BYOC | Beyond Commerce, Inc. | USD 0 | ▲ 0% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 15:26 UTC. This page is informational and not investment advice.